Burke RL - Search Results

1

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.

Pass RF, Duliegè AM, Boppana S, Sekulovich R, Percell S, Britt W, Burke RL. Pass RF, et al. Among authors: burke rl. J Infect Dis. 1999 Oct;180(4):970-5. doi: 10.1086/315022. J Infect Dis. 1999. PMID: 10479120 Clinical Trial.

2

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.

Frey SE, Harrison C, Pass RF, Yang E, Boken D, Sekulovich RE, Percell S, Izu AE, Hirabayashi S, Burke RL, Duliège AM. Frey SE, et al. Among authors: burke rl. J Infect Dis. 1999 Nov;180(5):1700-3. doi: 10.1086/315060. J Infect Dis. 1999. PMID: 10515836 Clinical Trial.

3

Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine.

Kohl S, Charlebois ED, Sigouroudinia M, Goldbeck C, Hartog K, Sekulovich RE, Langenberg AG, Burke RL. Kohl S, et al. Among authors: burke rl. J Infect Dis. 2000 Jan;181(1):335-9. doi: 10.1086/315208. J Infect Dis. 2000. PMID: 10608784

4

Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines.

Wang JB, Adler SP, Hempfling S, Burke RL, Duliège AM, Starr SE, Plotkin SA. Wang JB, et al. Among authors: burke rl. J Infect Dis. 1996 Aug;174(2):387-92. doi: 10.1093/infdis/174.2.387. J Infect Dis. 1996. PMID: 8699071

5

Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers.

Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP. Mitchell DK, et al. Among authors: burke rl. Pediatr Infect Dis J. 2002 Feb;21(2):133-8. doi: 10.1097/00006454-200202000-00009. Pediatr Infect Dis J. 2002. PMID: 11840080 Clinical Trial.

6

Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin.

Drulak MW, Malinoski FJ, Fuller SA, Stewart SS, Hoskin S, Duliege AM, Sekulovich R, Burke R, Winston S. Drulak MW, et al. Viral Immunol. 2000;13(1):49-56. doi: 10.1089/vim.2000.13.49. Viral Immunol. 2000. PMID: 10733168 Clinical Trial.

7

Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes.

Straus SE, Corey L, Burke RL, Savarese B, Barnum G, Krause PR, Kost RG, Meier JL, Sekulovich R, Adair SF, et al. Straus SE, et al. Among authors: burke rl. Lancet. 1994 Jun 11;343(8911):1460-3. doi: 10.1016/s0140-6736(94)92581-x. Lancet. 1994. PMID: 7911177 Clinical Trial.

8

Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine.

Ashley RL, Crisostomo FM, Doss M, Sekulovich RE, Burke RL, Shaughnessy M, Corey L, Polissar NL, Langenberg AG. Ashley RL, et al. Among authors: burke rl. J Infect Dis. 1998 Jul;178(1):1-7. doi: 10.1086/515611. J Infect Dis. 1998. PMID: 9652416

9

Limited variability of glycoprotein gene sequences and neutralizing targets in herpes simplex virus type 2 isolates and stability on passage in cell culture.

Terhune SS, Coleman KT, Sekulovich R, Burke RL, Spear PG. Terhune SS, et al. Among authors: burke rl. J Infect Dis. 1998 Jul;178(1):8-15. doi: 10.1086/515590. J Infect Dis. 1998. PMID: 9652417

10

Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients.

Marshall GS, Li M, Stout GG, Louthan MV, Duliège AM, Burke RL, Hunt LA. Marshall GS, et al. Among authors: burke rl. Viral Immunol. 2000;13(3):329-41. doi: 10.1089/08828240050144653. Viral Immunol. 2000. PMID: 11016597

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters